pSivida (NASDAQ:PSDV) has been given a $5.00 price objective by analysts at B. Riley in a research note issued on Monday. The firm presently has a “buy” rating on the stock. B. Riley’s price target indicates a potential upside of 293.70% from the company’s current price. B. Riley also issued estimates for pSivida’s Q2 2018 earnings at ($0.14) EPS, Q3 2018 earnings at ($0.15) EPS, Q4 2018 earnings at ($0.13) EPS, FY2018 earnings at ($0.56) EPS, FY2019 earnings at ($0.49) EPS, FY2020 earnings at ($0.31) EPS, FY2021 earnings at ($0.14) EPS and FY2022 earnings at $0.00 EPS.
Several other analysts have also recently weighed in on the stock. Laidlaw initiated coverage on shares of pSivida in a research report on Wednesday, November 8th. They set a “buy” rating and a $5.00 price objective on the stock. HC Wainwright set a $5.00 price objective on shares of pSivida and gave the company a “buy” rating in a research report on Wednesday, October 11th. Finally, ValuEngine cut shares of pSivida from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $7.57.
Shares of pSivida (NASDAQ:PSDV) opened at $1.27 on Monday. pSivida has a 52-week low of $1.03 and a 52-week high of $2.45.
An institutional investor recently raised its position in pSivida stock. Renaissance Technologies LLC increased its holdings in pSivida Corp. (NASDAQ:PSDV) by 6.2% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 963,043 shares of the company’s stock after purchasing an additional 56,043 shares during the quarter. Renaissance Technologies LLC owned 2.82% of pSivida worth $1,656,000 as of its most recent filing with the Securities & Exchange Commission. 9.70% of the stock is currently owned by institutional investors.
pSivida Company Profile
pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.
What are top analysts saying about pSivida Corp.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for pSivida Corp. and related companies.